Exodus Point Capital Management, LP Inhibrx, Inc. Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$15.75 - $26.31 $172,588 - $288,304	10,958 New	10,958 $201,000
Q3 2022 Nov 10, 2022	SELL	$11.58 - $24.73 $778,558 - $1.66 Million	-67,233 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$8.52 - $25.26 $572,825 - $1.7 Million	67,233 New	67,233 $763,000
Q4 2020 Feb 16, 2021	SELL	$15.96 - $50.0 $225,275 - $705,750	-14,115 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$16.77 - $20.65 $236,708 - $291,474	14,115 New	14,115 $254,000

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.